Losmapimod, a potential oral treatment for facioscapulohumeral muscular dystrophy (FSHD), missed its main goal in a recent Phase…
Articles by Forest Ray PhD
AMRA Medical’s new MRI method was found to play an instrumental role in detecting changes in disease progression among…
Givinostat halted muscle shrinkage and fat infiltration in men with Becker muscular dystrophy (BMD) despite failing to ease…
FibroGen has begun a second Phase 3 clinical trial of pamrevlumab, given with corticosteroids, among boys with…
Editor’s note: The Muscular Dystrophy News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference,…
Treatment with givinostat alongside corticosteroids continues to delay disease progression — and maintain patients’ ability to walk — in…
In the first year since Parent Project Muscular Dystrophy (PPMD) and Thread launched a mobile app aimed at…
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected…
The first boy has been dosed in a Phase 3 trial testing Pfizer‘s gene therapy, PF-06939926, in treating Duchenne…
The investigational gene therapy SRP-9001 safely leads to the production of a functional form of dystrophin in boys with…